ClinicalTrials.gg
Status unknownNCT04843254Updated Mar 31, 2022

Translation of Stroke Specific Quality of Life Questionnaire Into Local Languages of Pakistan

An observational study in Stroke, sponsored by Riphah International University. Status unknown at 1 site in Pakistan. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Riphah International University · Observational

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
1,125
Ages
40 Years to 70 Years
Sex
All
01

Study summary

The aim of the present study is to translate the Stroke Specific Quality of Life Questionnaire into local languages of Pakistan along with validation of the translated versions by evaluating their validity and reliability in the people of Pakistan, speaking respective languages and suffering from a stroke. No such study has been previously conducted in the Pakistan region which translates the specific questionnaire and follows the proper cross-culture adaptation protocol.

Read the detailed description

The stroke-Specific Quality of Life Scale is regarded as one of the most extensive and more commonly utilized patient-centred and self-reported measure of outcomes in the stroke population. The SS-QoL scale is a health-related outcome measure that comprises 49 items in 12 areas of vision, mobility, thinking, social roles, self-care, language, personality, family roles, work/productivity, upper limb function, mood and energy. It covers a more extensive inclusion of capacities ordinarily influenced by stroke.

The Stroke Specific Quality of Life questionnaire, originally developed in English, has been translated into many languages to assess for its validity and reliability ever since, but not any of the Pakistani native versions are made or tested. Previous studies have shown that the translation of the scale would end up giving a standard measure to be utilized in clinical practices and research studies while sanctioning clinicians and specialists to share information and have an insight into patient's health-related concerns post-stroke. Thus, it is imperative to translate this questionnaire into psychometrically sound versions of indigenous Pakistani languages such as Urdu, Punjabi, Sindhi, Balochi and Pashto. This may promote an easy understanding of the local population in Pakistan where the languages are spoken and will provide a valid measure of stroke-specific health outcomes to be clinically utilized by practitioners and researchers across the country.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • SSQoL
  • Stroke Specific Quality of Life
  • Tool Translation
  • Validity
  • Reliability
03

In context

Stroke

7,443 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

This study's planned enrollment of 1,125 is above the median of 160 across 1,729 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,176 studies on the registry; 637 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

To meet inclusion criteria, participants diagnosed with stroke (sub-acute/chronic stage), clinically stable, between age 40-70 years and able to read and complete the local language version of SSQoL. Then patient response will be checked on the translated versions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients post-stroke (sub-acute/chronic stage)
  • Participants belonging to Urdu, Punjabi, Sindhi, Balochi and Pashto speaking class
  • Patients should be capable to complete the questionnaire without any help.

Exclusion criteria

Exclusion Criteria:

  • Healthy population
  • Patients at the acute stage of stroke/ TIA.
  • Individuals diagnosed with conditions other than stroke.
  • Individuals with language/ memory problems.
  • Individuals with disability due to any structural/congenital cause.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
1,125 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Cross-Cultural Translation of Stroke Specific Quality of Life Scale into local languages of Pakistan

    The Stroke Specific Quality of Life Scale (SSQoL) is regarded as one of the most extensive and more commonly utilized patient-centred and self-reported measure of outcomes in the stroke population. It is a health-related stroke outcome measure intended to gather all the relevant concerns significant to the stroke population. The responses are obtained via a progression of a series of centred meetings and interviews with concerned post-stroke patients to survey personal satisfaction. The SS-QoL comprises 49 items in 12 areas of vision, mobility, thinking, social roles, self-care, language, personality, family roles, work/productivity, upper limb function, mood and energy. The patient responses are appraised on a Likert scale consisting of 5 points with greater scores demonstrating better capacity. It covers a more extensive inclusion of capacities ordinarily influenced by stroke. Its translation is to be done in the local languages of Pakistan through a rigorous and approved process.

    Time frame: 6 months

Secondary outcomes

  1. Reliability and Validity of translated versions

    To determine reliability and validity of cross-culturally adapted and the translated versions of SSQoL in stroke patients with respective languages. Reliability or reproducibility refers to the ability of a measure to produce the same results when administered at two or more interval between different visits of the patient and validity is how accurate the tool measures an item it is supposed to. Thus these both are to measured through various parameters to validate the translated versions as appropriate and applicable.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Physiotherapy Department WIRS
    Abbottabad, KPK 22010, Pakistan
    • Umber Fatima, M.Phil · Contact · umber.fatima11@gmail.com · 03314721691
    • Ayesha Javed, MSPT(NMPT*) · Principal investigator
    Recruiting
08

References and documents

Publications

  • Williams LS, Weinberger M, Harris LE, Clark DO, Biller J. Development of a stroke-specific quality of life scale. Stroke. 1999 Jul;30(7):1362-9. doi: 10.1161/01.str.30.7.1362. PubMed 10390308 ↗
  • Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HC. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010 May;19(4):539-49. doi: 10.1007/s11136-010-9606-8. Epub 2010 Feb 19. PubMed 20169472 ↗
  • Ganvir S, Harishch M, Kunde C. Validation of Marathi Version of Stroke-specific Quality of Life. Ann Indian Acad Neurol. 2018 Oct-Dec;21(4):290-293. doi: 10.4103/aian.AIAN_449_17. PubMed 30532359 ↗
  • Sallam SA, Al-Khamis FA, Muaidi QI, Abdulla FA. Translation and validation of the stroke specific quality of life scale into Arabic. NeuroRehabilitation. 2019;44(2):283-293. doi: 10.3233/NRE-182552. PubMed 31006693 ↗
  • Mahmoodi M, Safari A, Vossoughi M, Golbon-Haghighi F, Kamali-Sarvestani M, Ghaem H, Borhani-Haghighi A. Stroke specific quality of life questionnaire: Test of reliability and validity of the Persian version. Iran J Neurol. 2015 Apr 4;14(2):94-100. PubMed 26056554 ↗
  • Lo SH, Chang AM, Chau JP. Establishing equivalence of a Chinese version of the stroke specific quality of life measure for stroke survivors. Disabil Rehabil. 2017 Jun;39(11):1079-1086. doi: 10.1080/09638288.2016.1178348. Epub 2016 May 23. PubMed 27216634 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Apr 2022, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 13, 2021
StartActual
Mar 10, 2021
Primary completionEst.
Apr 22, 2022
CompletionEst.
Apr 30, 2022
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04843254
Responsible party
Sponsor
First posted
Apr 13, 2021
Start date
Mar 10, 2021
Primary completion
Apr 22, 2022 (estimated)
Completion
Apr 30, 2022 (estimated)
Last update
Mar 31, 2022

Study contacts

Imran Amjad, PhD
Contact
imran.amjad@riphah.edu.pk
03324390125
Ayesha Javed, MSPT(NMPT*)
Contact
ayesha11492@gmail.com
03165278975
Imran Amjad, PhD
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion